Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,741 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Emergence of genomic diversity and recurrent mutations in SARS-CoV-2.
van Dorp L, Acman M, Richard D, Shaw LP, Ford CE, Ormond L, Owen CJ, Pang J, Tan CCS, Boshier FAT, Ortiz AT, Balloux F. van Dorp L, et al. Among authors: pang j. Infect Genet Evol. 2020 Sep;83:104351. doi: 10.1016/j.meegid.2020.104351. Epub 2020 May 5. Infect Genet Evol. 2020. PMID: 32387564 Free PMC article.
Evolution of viral variants in remdesivir-treated and untreated SARS-CoV-2-infected pediatrics patients.
Boshier FAT, Pang J, Penner J, Parker M, Alders N, Bamford A, Grandjean L, Grunewald S, Hatcher J, Best T, Dalton C, Bynoe PD, Frauenfelder C, Köeglmeier J, Myerson P, Roy S, Williams R, de Silva TI, Goldstein RA, Breuer J; COVID-19 Genomics UK (COG-UK) consortium. Boshier FAT, et al. Among authors: pang j. J Med Virol. 2022 Jan;94(1):161-172. doi: 10.1002/jmv.27285. Epub 2021 Sep 4. J Med Virol. 2022. PMID: 34415583 Free PMC article.
SARS-CoV-2 lineage B.1.1.7 is associated with greater disease severity among hospitalised women but not men: multicentre cohort study.
Stirrup O, Boshier F, Venturini C, Guerra-Assunção JA, Alcolea-Medina A, Beckett A, Charalampous T, da Silva Filipe A, Glaysher S, Khan T, Kulasegaran Shylini R, Kele B, Monahan I, Mollett G, Parker M, Pelosi E, Randell P, Roy S, Taylor J, Weller S, Wilson-Davies E, Wade P, Williams R; COG-UK-HOCI Variant substudy consortium; COVID-19 Genomics UK (COG-UK) consortium; Copas A, Cutino-Moguel MT, Freemantle N, Hayward AC, Holmes A, Hughes J, Mahungu T, Nebbia G, Partridge D, Pope C, Price J, Robson S, Saeed K, de Silva T, Snell L, Thomson E, Witney AA, Breuer J. Stirrup O, et al. BMJ Open Respir Res. 2021 Sep;8(1):e001029. doi: 10.1136/bmjresp-2021-001029. BMJ Open Respir Res. 2021. PMID: 34544733 Free PMC article.
Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity.
Kaptein SJF, Jacobs S, Langendries L, Seldeslachts L, Ter Horst S, Liesenborghs L, Hens B, Vergote V, Heylen E, Barthelemy K, Maas E, De Keyzer C, Bervoets L, Rymenants J, Van Buyten T, Zhang X, Abdelnabi R, Pang J, Williams R, Thibaut HJ, Dallmeier K, Boudewijns R, Wouters J, Augustijns P, Verougstraete N, Cawthorne C, Breuer J, Solas C, Weynand B, Annaert P, Spriet I, Vande Velde G, Neyts J, Rocha-Pereira J, Delang L. Kaptein SJF, et al. Among authors: pang j. Proc Natl Acad Sci U S A. 2020 Oct 27;117(43):26955-26965. doi: 10.1073/pnas.2014441117. Epub 2020 Oct 9. Proc Natl Acad Sci U S A. 2020. PMID: 33037151 Free PMC article.
The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model.
Abdelnabi R, Foo CS, Kaptein SJF, Zhang X, Do TND, Langendries L, Vangeel L, Breuer J, Pang J, Williams R, Vergote V, Heylen E, Leyssen P, Dallmeier K, Coelmont L, Chatterjee AK, Mols R, Augustijns P, De Jonghe S, Jochmans D, Weynand B, Neyts J. Abdelnabi R, et al. Among authors: pang j. EBioMedicine. 2021 Oct;72:103595. doi: 10.1016/j.ebiom.2021.103595. Epub 2021 Sep 24. EBioMedicine. 2021. PMID: 34571361 Free PMC article.
3,741 results